Immix Biopharma Investor Presentation Deck slide image

Immix Biopharma Investor Presentation Deck

IMX-110 MoA: Tissue-Specific Therapeutic™ with TME Normalization™ Technology www. wwwwww -PEG-PE -DOX - CUR ● www. www. www. 0 14-16nm diameter wwwww www. IgG Antibody: 10-15nm diameter BCL-X BCL2 -my urvivi PI3K AKT IMX-110 Upregulation in Cancer ¡MX-110 Downregulation. O O O O NFKB COX2 spase O Jak TAT3 ¡MX-110 DNA Damage ¡MX-110 Upregulation X iMX-110 Disperses Throughout Cell IMX-110 is a negatively-charged Tissue-Specific Therapeutic™M built on our TME Normalization™ Technology encapsulating a synergistic 5:1 ratio of poly-kinase inhibitor (polyphenol curcuminoid complex, or PCC) and apoptosis inducer (PEG-PE doxorubicin complex) delivered deep into the TME. First Oncology Micelle to achieve "small molecule penetration" Electrostatic charge attracts to tumor like a magnet Resulting in 1,200% increase in apoptosis (tumor cell death) vs. conventional therapies D Li (11) IMX-110 - Key Characteristics Get There: Deliver Payload Deep Into the Tumor Microenvironment Stay There: Accumulate in Tumors Kill Tumors: 12x Tumor Killing vs SoC 1% % of dose / g organ Control 10. (g) 8. 1 0 intensity (a.u.) →→→ 15% 600 200 -200 Free DOX -12nm -60nm -125nm 10 20 30 40 50 Time (h) ●●● IMMIX S BIOPHARMA 40 80 distance from vessel (μm)-> (Adapted from Popovic et al, 2010) Caspase 3/7 Increase (%) vs. Control (empty micelle) as an indicator of tumor apoptosis, after 24h -1,200% increase --181% penetration depth 35% Micellular DOX Free DOX 53% DOX micelles CUR micelles iMX-110 38 Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol. 2022.281628. Epub ahead of print. PMID: 36200421. Stan, S. D. et al. Nat. Rev. Gastroenterol. Hepatol. 7, 347-356 (2010); published online 4 May 2010. http://www.nature.com/doifinder/10.1038/nrgastro.2010.61. Popovic et al, A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl. 2010 Nov 8; 49(46): 8649-8652. https://dx.doi.org/10.1002%2Fanie.201003142; M Yokoyama, T Okano, Y Sakurai, S Fukushima, K Okamoto, K Kataoka. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. https://doi.org/10.3109/10611869909085500; Sarisozen et. al. (2016- https://doi.org/10.1016/j.ejpb.2016.08.013).
View entire presentation